

Perkutane Mitralklappenrekonstruktion

C. Iliadis, E. Kuhn, S. Baldus

Literatur:

1. Nkomo VT et al. Burden of valvular heart diseases: a population-based study. *Lancet* 2006; 368(9540): 1005–1011. doi:10.1016/S0140-6736(06)69208-8
2. Dziadzko V et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. *Lancet* 2018; 391(10124): 960–969. doi:10.1016/S0140-6736(18)30473-2
3. Dziadzko V et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. *Eur heart J* 2019; 40(27): 2194–2202. doi:10.1093/eurheartj/ehz314
4. Baumgartner H et al. Group ESCSD. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur heart J* 2017; 38(36): 2739–2791. doi:10.1093/eurheartj/ehx391
5. Feldman T et al. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med* 2011; 364(15): 1395–1406. doi:10.1056/NEJMoa1009355
6. Feldman T et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. *J Am Coll Cardiol* 2015; 66(25): 2844–2854. doi:10.1016/j.jacc.2015.10.018
7. Otto CM et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2021; 143(5): e72–e227. doi:10.1161/CIR.0000000000000923
8. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur heart J* 2016; 37(27): 2129–2200. doi:10.1093/eurheartj/ehw128
9. Lowes BD et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. *Am J Cardiol* 1999; 83(8): 1201–1205. doi:10.1016/s0002-9149(99)00059-4
10. Kang DH et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. *Circulation* 2019; 139(11): 1354–1365 doi:10.1161/CIRCULATIONAHA.118.037077
11. Seneviratne B et al. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. *Br Heart J* 1994; 72 (1): 63–68. doi:10.1136/hrt.72.1.63
12. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2019; 381(21): 1995–2008. doi:10.1056/NEJMoa1911303
13. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med* 2020; 383(15): 1413–1424. doi:10.1056/NEJMoa2022190
14. Mason T et al. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. *JACC Cardiovasc Imaging* 2021. doi:10.1016/j.jcmg.2020.10.017
15. Onishi T et al. Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome. *Circulation Heart failure* 2013; 6(4): 685–693. doi:10.1161/CIRCHEARTFAILURE.112.000112
16. van Bommel RJ et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. *Circulation* 2011; 124(8): 912–919. doi:10.1161/CIRCULATIONAHA.110.009803
17. Goldstein D et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. *N Engl J Med* 2016; 374(4): 344–353. doi:10.1056/NEJMoa1512913
18. Iliadis C et al. Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review. *Clinical research in cardiology : official journal of the German Cardiac Society* 2017; 106(12): 1005–1017. doi:10.1007/s00392-017-1150-x
19. Stone GW et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N Engl J Med* 2018; 379(24): 2307–2318. doi:10.1056/NEJMoa1806640

20. Obadia JF et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N Engl J Med* 2018; 379(24): 2297–2306. doi:10.1056/NEJMoa1805374
21. lung B et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. *Eur J Heart Fail* 2019; 21(12): 1619–1627. doi:10.1002/ejhf.1616
22. Grayburn PA et al. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. *JACC Cardiovasc Imaging* 2019; 12(2): 353–362. doi:10.1016/j.jcmg.2018.11.006
23. Lindenfeld J et al. Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. *JAMA cardiology* 2021; 6(4): 427–436. doi:10.1001/jamacardio.2020.7200
24. Mack MJ et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. *J Am Coll Cardiol* 2021; 77(8): 1029–1040. doi:10.1016/j.jacc.2020.12.047
25. Lim DS et al. Transcatheter Valve Repair for Patients With Mitral Regurgitation: 30-Day Results of the CLASP Study. *JACC Cardiovascular interventions* 2019; 12(14): 1369–1378. doi:10.1016/j.jcin.2019.04.034
26. Mauri V et al. German Multicenter Experience With a New Leaflet-Based Transcatheter Mitral Valve Repair System for Mitral Regurgitation. *JACC Cardiovascular interventions* 2020; 13(23): 2769–2778. doi:10.1016/j.jcin.2020.08.025
27. Witte KK et al. The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation. *JACC Heart Fail* 2019; 7(11): 945–955. doi:10.1016/j.jchf.2019.06.011
28. Lipiecki J et al. Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon Device. *Cardiovasc Revasc Med* 2020; 21(6): 712–716. doi:10.1016/j.carrev.2020.02.012
29. Messika-Zeitoun D et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. *Eur heart J* 2019; 40(5): 466–472. doi:10.1093/eurheartj/ehy424
30. Baldus S et al. Interventionelle Therapie von AV-Klappenerkrankungen – Fokus Mitralklappeninsuffizienz. *Kardiologie* 2018; 12: 128–144. doi:10.1007/s12181-018-0232-y
31. Hensey M et al. Transcatheter Mitral Valve Replacement: An Update on Current Techniques, Technologies, and Future Directions. *JACC Cardiovascular interventions* 2021; 14 (5): 489–500. doi:10.1016/j.jcin.2020.12.038
32. Sorajja P et al. Initial Feasibility Study of a New Transcatheter Mitral Prosthesis: The First 100 Patients. *J Am Coll Cardiol* 2019; 73(11): 1250–1260. doi:10.1016/j.jacc.2018.12.066
33. Muller D et al. Two-Year Outcomes of Tendyne Transcatheter Mitral Valve Implantation to Treat Symptomatic, Severe Mitral Regurgitation. Presented at PCR E-Course 2020
34. Lisko JC et al. Antegrade Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction: A Simplified Technique From Bench to Bedside. *Circ Cardiovasc Interv* 2020; 13(6): e008903. doi:10.1161/CIRCINTERVENTIONS.119.008903

Klappenerhaltende Aortenklappenchirurgie

M. Lal Shrestha, E. Beckmann

Literatur:

1. Bentall H & De Bono A. A technique for complete replacement of the ascending aorta. *Thorax* 1968; 23(4):338–9
2. Misawa Y. Valve-related complications after mechanical heart valve implantation. *Surg Today* 2015; 45(10): 1205–9
3. Chan V et al. Reoperation of left heart valve bioprostheses according to age at implantation. *Circulation* 2011; 124(11 Suppl): 75-80.

4. Sarsam MA & Yacoub M. Remodeling of the aortic valve anulus. *J Thorac Cardiovasc Surg.* 1993; 105(3):435–8
5. David TE & Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. *J Thorac Cardiovasc Surg.* 1992 Apr;103(4):617–21; discussion 622
6. Erbel R et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014; 35(41): 2873–926
7. Leyh RG et al. Valve-sparing aortic root replacement (remodeling/reimplantation) in acute type A dissection. *Ann Thorac Surg* 2000; 70(1): 21–4
8. Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; 38(36): 2739–91
9. El Khoury G et al. Functional classification of aortic root/valve abnormalities and their correlation with etiologies and surgical procedures. *Curr Opin Cardiol* 2005; 20(2): 115–21
10. David TE et al. Replacement of the ascending aorta with reduction of the diameter of the sinotubular junction to treat aortic insufficiency in patients with ascending aortic aneurysm. *J Thorac Cardiovasc Surg* 2007; 133(2): 414–8
11. Hui SK et al. The aortic root does not dilate over time after replacement of the aortic valve and ascending aorta in patients with bicuspid or tricuspid aortic valves. *J Thorac Cardiovasc Surg* 2018; 156(1): 5-13.e1
12. Yacoub MH et al. Late results of a valve-preserving operation in patients with aneurysms of the ascending aorta and root. *J Thorac Cardiovasc Surg* 1998; 115(5): 1080–90
13. Lenoir M et al. Reimplantation versus remodelling with ring annuloplasty: comparison of mid-term outcomes after valve-sparing aortic root replacement. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2018; 54(1): 48–54
14. Erasmi AW et al. Up to 7 years' experience with valve-sparing aortic root remodeling/reimplantation for acute type A dissection. *Ann Thorac Surg* 2003; 76(1): 99–104
15. Graeter TP et al. Valve-preserving operation in acute aortic dissection type A. *Ann Thorac Surg* 2000; 70(5): 1460–5
16. Subramanian S et al. Valve-sparing root reconstruction does not compromise survival in acute type A aortic dissection. *Ann Thorac Surg* 2012; 94(4): 1230–4
17. Schäfers H-J et al. Reexamining remodeling. *J Thorac Cardiovasc Surg* 2015; 149(2 Suppl): S30–36
18. de Kerchove L et al. The role of annular dimension and annuloplasty in tricuspid aortic valve repair. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2016; 49(2): 428–37
19. Schneider U et al. Valve-sparing aortic root replacement in patients with Marfan syndrome-the Homburg experience. *Ann Cardiothorac Surg* 2017; 6(6): 697–703
20. Leyh RG et al. High failure rate after valve-sparing aortic root replacement using the “remodeling technique” in acute type A aortic dissection. *Circulation* 2002; 106(12 Suppl 1): I229–233
21. Bethea BT et al. Results of aortic valve-sparing operations: experience with remodeling and reimplantation procedures in 65 patients. *Ann Thorac Surg* 2004; 78(3): 767–72
22. Kari FA et al. Survival and freedom from aortic valve-related reoperation after valve-sparing aortic root replacement in 1015 patients. *Interact Cardiovasc Thorac Surg* 2016; (4): 431–8
23. Svensson LG et al. Results of matching valve and root repair to aortic valve and root pathology. *J Thorac Cardiovasc Surg* 2011; 142(6): 1491–1498
24. Kunihara T et al. Aortic annulus does not dilate over time after aortic root remodeling with or without annuloplasty. *J Thorac Cardiovasc Surg* 2018; 155(3): 885–894.e3
25. Miller DC. Valve-sparing aortic root replacement in patients with the Marfan syndrome. *J Thorac Cardiovasc Surg* 2003; 125(4): 773–8
26. Erasmi AW et al. Remodeling or reimplantation for valve-sparing aortic root surgery? *Ann Thorac Surg* 2007; 83(2): 752–756
27. Shrestha ML et al. Elective David I Procedure Has Excellent Long-Term Results: 20-Year Single-Center Experience. *Ann Thorac Surg* 2018; 105(3): 731–8

28. Beckmann E et al. Valve-sparing David I procedure in acute aortic type A dissection: a 20-year experience with more than 100 patients†. *Eur J Cardiothorac Surg* 2017; 52(2): 319–24
29. Shrestha M et al. Long-term results after aortic valve-sparing operation (David I). *Eur J Cardiothorac Surg* 2012
30. Klotz S et al. Survival and reoperation pattern after 20 years of experience with aortic valve-sparing root replacement in patients with tricuspid and bicuspid valves. *J Thorac Cardiovasc Surg* 2018; 155(4): 1403–11
31. David TE et al. Long-term results of aortic root repair using the reimplantation technique. *J Thorac Cardiovasc Surg* 2013; 145(3 Suppl): 22–25
32. David TE et al. Reimplantation of the aortic valve at 20 years. *J Thorac Cardiovasc Surg* 2017; 153(2): 232–8
33. De Paulis R et al. A new aortic Dacron conduit for surgical treatment of aortic root pathology. *Ital Heart J Off J Ital Fed Cardiol* 2000; 1(7): 457–63
34. Beckmann E et al. Comparison of Two Strategies for Aortic Valve-Sparing Root Replacement. *Ann Thorac Surg* 2020; 109(2): 505–11
35. Beckmann E et al. Aortic valve-sparing root replacement in patients with bicuspid aortic valve: long-term outcome with the David I procedure over 20 years. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2020
36. Hess PJ et al. The Florida sleeve: a new technique for aortic root remodeling with preservation of the aortic valve and sinuses. *Ann Thorac Surg* 2005; 80(2): 748–50
37. Hetzer R et al. Remodeling of aortic root by annular reconstruction and plication of sinuses of Valsalva. *J Card Surg* 2008; 23(1): 49–51
38. Shrestha M et al. Valve-sparing aortic root stabilization in acute type a aortic dissection. *Asian Cardiovasc Thorac Ann* 2009; 17(1): 22–4
39. Komoda T et al. Reverse graft placement in the Florida sleeve procedure for aortic root aneurysm. *Ann Thorac Surg* 2013; 95(2): 723–5
40. Aalaei-Andabili SH et al. Florida Sleeve Procedure Is Durable and Improves Aortic Valve Function in Marfan Syndrome Patients. *Ann Thorac Surg* 2017; 104(3): 834–9
41. Aicher D et al. Cusp repair in aortic valve reconstruction: does the technique affect stability? *J Thorac Cardiovasc Surg* 2007; 134(6): 1533–8
42. Sievers H-H & Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. *J Thorac Cardiovasc Surg* 2007; 133(5): 1226–33
43. Price J et al. Long-term outcomes of aortic root operations for Marfan syndrome: A comparison of Bentall versus aortic valve-sparing procedures. *J Thorac Cardiovasc Surg* 2016; 151(2): 330–6
44. Kvitting J-PE et al. David valve-sparing aortic root replacement: equivalent mid-term outcome for different valve types with or without connective tissue disorder. *J Thorac Cardiovasc Surg* 2013; 145(1): 117–26
45. Martens A et al. Valve-sparing aortic root replacement (David I procedure) in Marfan disease: single-centre 20-year experience in more than 100 patients†. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2019; 55(3): 476–83
46. Flynn CD et al. Systematic review and meta-analysis of surgical outcomes in Marfan patients undergoing aortic root surgery by composite-valve graft or valve sparing root replacement. *Ann Cardiothorac Surg* 2017; 6(6): 570–81
47. Loeys BL et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. *Nat Genet* 2005; 37(3): 275–81
48. Williams JA et al. Early surgical experience with Loeys-Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. *Ann Thorac Surg* 2007; 83(2): 757–763
49. Patel ND et al. Valve-sparing aortic root replacement in Loeys-Dietz syndrome. *Ann Thorac Surg* 2011; 92(2): 556–60
50. Patel ND et al. Cardiovascular operations for Loeys-Dietz syndrome: Intermediate-term results. *J Thorac Cardiovasc Surg* 2017; 153(2): 406–12

Erkrankungen der Mitralklappe und ihre chirurgischen Therapiemöglichkeiten

A. Diegeler, F. Lakew, A. Sodah

Literatur:

1. Carrel T et al. Behandlung von Erkrankungen der Mitralklappe. SWISS MEDICAL FORUM – SCHWEIZERISCHES MEDIZIN-FORUM 2016; 16(5): 114–120
2. Jung B et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal 2003; 24: 1231–1243
3. Carpentier A et al. CARPENTIER'S Reconstructive Valve Surgery. From Valve Analysis to Valve Reconstruction. Saunders Elsevier 2010
4. Spiekler M et al. Moderne Diagnostik der Mitralklappe- und Trikuspidalklappe – was ist wirklich notwendig? Aktuell Kardiologie 2017; 6: 265–270
5. Zoghbi WA et al. Recommendations for Evaluation of the Severity of Native Valvular Regurgitation with Two-dimensional and Doppler Echocardiography. Journal of the American Society of Echocardiography, 2003; 16(7): 777–802
6. Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 2017; 38: 2739–2791
7. Jessurun ER et al. Mitral valve surgery and atrial fibrillation: is atrial fibrillation surgery also needed? European Journal of Cardio-thoracic Surgery 2000; 17(5): 530–7
8. Goldstone AB et al. Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement. N Engl J Med 2017; 377: 1847–57
9. Hoffmann G et al. Verbesserte Haltbarkeit von biologischen Herzklappen. Deutsches Ärzteblatt 2008; 105(8): 22
10. van der Merwe J & Casselman F: Mitral Valve Replacement – Current and Future Perspectives. Open Journal of Cardiovascular Surgery; 9: 1–6
11. DGTHG Leistungsstatistik 2020, https://www.dgthg.de/sites/default/files/Grafiken-DGTHG-Leistungsstatistik%202020_free-access_0.pdf, abgerufen am 10.5.2021
12. Perier P. A New Paradigm for the Repair of Posterior Leaflet Prolapse: Respect Rather Than Resect. Operative Techniques in Thoracic and Cardiovascular Surgery 2005; 10(3): 180–193
13. Davierwala PM et al. Minimally invasive mitral valve surgery: "The Leipzig experience". Ann Cardiothorac Surg 2013; 2(6): 744–750
14. Perier P, et al. Rate of repair in minimally invasive mitral valve surgery. Ann Cardiothorac Surg 2013; 2(6): 751–757
15. Perier P. Toward a new paradigm for the reconstruction of posterior leaflet prolapse: midterm results of the "respect rather than resect" approach. Ann Thorac Surg 2008; 86: 718–25
16. Bush B et al. Robotic mitral valve surgery – current status and future directions. Ann Cardiothorac Surg 2013; 2(6): 814–817
17. David TE et al. Late Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease. Circulation 2013; 127(14): 1485–92
18. Deutsche Gesellschaft für Kardiologie, Pocket-Leitlinie: Management von Herzklappenerkrankungen, https://leitlinien.dgk.org/files/27_2017_pocket_leitlinien_herzklappen.pdf

Chirurgie der Trikuspidalklappe

A. Cetinkaya

Literatur

1. Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017. 38(36): 2739–2791
2. Beckmann A et al. German Heart Surgery Report 2019: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery. *Thorac Cardiovasc Surg* 2020. 68(4): 263–276
3. Shiran A & Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. *J Am Coll Cardiol* 2009. 53(5): 401–8
4. Topilsky Y et al., Clinical outcome of isolated tricuspid regurgitation. *JACC Cardiovasc Imaging* 2014. 7(12): 1185–94.
5. Prihadi EA et al. Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. *Eur Heart J* 2018. 39(39): 3574–3581
6. Benfari G et al. Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction. *Circulation* 2019. 140(3): 196–206
7. Wang N et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. *Eur Heart J* 2019. 40(5): 476–484
8. Zack CJ et al. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. *J Am Coll Cardiol* 2017. 70(24): 2953–2960
9. Dietz MF et al. Prognostic Implications of Right Ventricular Remodeling and Function in Patients With Significant Secondary Tricuspid Regurgitation. *Circulation* 2019. 140(10): 836–845
10. Dreyfus J et al. Comparison of 2-Dimensional, 3-Dimensional, and Surgical Measurements of the Tricuspid Annulus Size: Clinical Implications. *Circ Cardiovasc Imaging* 2015. 8(7): e003241
11. Carpentier A et al. A new reconstructive operation for correction of mitral and tricuspid insufficiency. *J Thorac Cardiovasc Surg* 1971. 61(1): 1–13
12. Dreyfus GD et al. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? *Ann Thorac Surg* 2005. 79(1): 127–32
13. Kim YJ et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. *Circulation* 2009. 120(17): 1672–8
14. Dreyfus GD et al. Tricuspid leaflet augmentation to address severe tethering in functional tricuspid regurgitation. *Eur J Cardiothorac Surg* 2008. 34(4): 908–10
15. Lapenna E et al. The clover technique for the treatment of complex tricuspid valve insufficiency: midterm clinical and echocardiographic results in 66 patients. *Eur J Cardiothorac Surg* 2010. 37(6): 1297–303
16. Eishi K et al. Spiral suspension, a novel repair technique for severe functional tricuspid regurgitation. *J Thorac Cardiovasc Surg* 2018. 156(2): 649–652
17. De Vega NG. [Selective, adjustable and permanent Annuloplasty. An original technic for the treatment of tricuspid insufficiency]. *Rev Esp Cardiol* 1972. 25(6): 555–6
18. Sales VL & McCarthy PM. Durability of functional tricuspid valve repair. *Semin Thorac Cardiovasc Surg* 2010. 22(1): 97–103
19. Alkhouli M et al. Comparative early outcomes of tricuspid Valve repair versus replacement for secondary tricuspid regurgitation. *Open Heart* 2018. 5(2): e000878
20. Kunadian B et al. Should the tricuspid valve be replaced with a mechanical or biological valve? *Interact Cardiovasc Thorac Surg* 2007. 6(4): 551–7
21. Kastengren M et al. Minimally invasive mitral valve surgery is associated with a low rate of complications. *J Intern Med* 2019. 286(6): 614–626
22. Singh SK et al. Midterm outcomes of tricuspid valve repair versus replacement for organic tricuspid disease. *Ann Thorac Surg* 2006. 82(5): 1735–41; discussion 1741

23. Kang Y et al. Fifteen-Year Outcomes After Bioprosthetic and Mechanical Tricuspid Valve Replacement. *Ann Thorac Surg* 2020. 110(5): 1564–1571
24. Spinner EM et al. In vitro characterization of the mechanisms responsible for functional tricuspid regurgitation. *Circulation* 2011. 124(8): 920–9
25. Dietz MF et al. Prognostic Implications of Staging Right Heart Failure in Patients With Significant Secondary Tricuspid Regurgitation. *JACC Heart Fail* 2020. 8(8): 627–636
26. Cetinkaya A et al. Long-term outcomes of concomitant tricuspid valve repair in patients undergoing mitral valve surgery. *J Cardiothorac Surg* 2020. 15(1): 210
27. Pfannmueller B et al. Concomitant Tricuspid Valve Repair during Minimally Invasive Mitral Valve Repair. *Thorac Cardiovasc Surg* 2020. 68(6): 486–491
28. Tang GH et al. Tricuspid valve repair with an Anuloplasty ring results in improved long-term outcomes. *Circulation* 2006. 114(1 Suppl): I577–81
29. Dreyfus J et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. *Eur Heart J* 2020. 41(45): 4304–4317
30. Axtell AL et al. Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation. *J Am Coll Cardiol* 2019. 74(6): 715–725

Der Siegeszug der TAVI: Eine Therapie für Alt und Jung?

T. J. Demal; D. Westermann; L. Conradi; H. Reichenspurner; A. Schäfer

Literatur

1. Andresen D. Deutscher Herzbericht. Dtsch Herzstiftung 2019
2. Leon MB et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med* 2010; 363: 1597–1607
3. Popma JJ et al. Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery. *J Am Coll Cardiol* 2014; 63: 1972–1981
4. Smith CR et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. *N Engl J Med* 2011; 364: 2187–2198
5. Abdel-Wahab M et al. Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement. *JAMA* 2014; 311: 1503
6. Leon MB et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016; 374: 1609–1620
7. Reardon MJ et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2017; 376: 1321–1331
8. Mack MJ et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med* 2019; 380: 1695–1705
9. Wendler O et al. SOURCE 3 Registry. *Circulation* 2017; 135: 1123–1132
10. Popma JJ et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med* 2019; 380: 1706–1715
11. Adams DH et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. *N Engl J Med* 2014; 370: 1790–1798
12. Schäfer A et al. TAVI for everyone: Where is the journey heading? *Zeitschrift für Herz-, Thorax- und Gefäßchirurgie* 2018; 155–164
13. Seiffert M et al. The DEDICATE Trial. *Eur Heart J* 2019; 40: 331–333
14. Vahanian A et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 2012; 33: 2451–2496

15. Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; 38
16. Otto CM et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* (2021). 143
17. Siontis GCM et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. *Eur Heart J* 2019; 40: 3143–3153
18. Mylotte D et al. Transcatheter heart valve failure: a systematic review. *Eur Heart J* 2015; 36: 1306–1327
19. Barbanti M & Tamburino C. Late degeneration of transcatheter aortic valves: pathogenesis and management. *EuroIntervention* 2016; 12: Y33–Y36
20. Blackman DJ et al. Long-Term Durability of Transcatheter Aortic Valve Prostheses. *J Am Coll Cardiol* 2019; 73: 537–545
21. Chiang YP et al. Survival and Long-term Outcomes Following Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients Aged 50 to 69 Years. *JAMA* 2014; 312: 1323
22. Fatima B et al. Durability Data for Bioprosthetic Surgical Aortic Valve: A Systematic Review. *JAMA Cardiol.* 2019; 4: 71–80
23. Aupart MR et al. Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1133 patients. *J Heart Valve Dis* 2006; 15: 768–75; discussion 775–6
24. Bocchino PP et al. Transcatheter Aortic Valve Replacement in Young Low-Risk Patients With Severe Aortic Stenosis: A Review. *Front Cardiovasc Med* 2020; 7: 1–11
25. Schewel D et al. Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 2015; 85: 502–514
26. Kodali S et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. *Eur Heart J* 2015; 36: 449–456
27. Mehaffey JH et al. Need for Permanent Pacemaker After Surgical Aortic Valve Replacement Reduces Long-Term Survival. *Ann Thorac Surg* 2018; 106: 460–465
28. Thyregod HGH et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis. *J Am Coll Cardiol* 2015; 65: 2184–2194
29. Toff W. The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial. American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology (ACC 2020/WCC) 2020